Amylyx presents full Phase 3 LUCIDITY results for avexitide in post-bariatric hypoglycemia at ObesityWeek
What happened: US biotech Amylyx Pharmaceuticals presented the full results of its Phase 3 LUCIDITY trial of avexitide in post-bariatric hypoglycemia (PBH) in a late-breaking oral session at the ObesityWeek 2026 Annual Meeting on 15 November 2026. PBH is a chronic condition in which people who have had weight-loss (bariatric) surgery, typically a Roux-en-Y gastric bypass, develop sudden, dangerous drops in blood sugar after meals; it affects an estimated 160,000 people in the US and has no approved treatment. Avexitide is an investigational first-in-class medicine that blocks the GLP-1 receptor, counteracting the exaggerated gut-hormone response believed to drive the condition.